C
ALLO icon

Covestor’s Allogene Therapeutics ALLO Stock Holding History

Covestor’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
36
– – ﹤0.01% 2211
2025
Q4 		$0 Hold
36
– – ﹤0.01% 2224
2025
Q3 		$0 Hold
36
– – ﹤0.01% 2235
2025
Q2 		$0 Sell
36
-3
-8% -$4 ﹤0.01% 2157
2025
Q1 		$0 Buy
39
+1
+3% +$2 ﹤0.01% 2165
2024
Q4 		$0 Buy
38
+20
+111% +$49 ﹤0.01% 2186
2024
Q3 		$0 Sell
18
-1
-5% -$3 ﹤0.01% 2163
2024
Q2 		$0 Hold
19
– – ﹤0.01% 2194
2024
Q1 		$0 Sell
19
-1
-5% -$4 ﹤0.01% 2192
2023
Q4 		$0 Sell
20
-2
-9% -$6 ﹤0.01% 2096
2023
Q3 		$0 Sell
22
-3
-12% -$13 ﹤0.01% 2064
2023
Q2 		$0 Buy
25
+12
+92% +$65 ﹤0.01% 2083
2023
Q1 		$0 Hold
13
– – ﹤0.01% 1963
2022
Q4 		$0 Sell
13
-1
-7% -$9 ﹤0.01% 2008
2022
Q3 		$0 Sell
14
-8
-36% -$109 ﹤0.01% 1929
2022
Q2 		$0 Sell
22
-6
-21% -$53 ﹤0.01% 1859
2022
Q1 		$0 Sell
28
-6
-18% -$62 ﹤0.01% 2061
2021
Q4 		$1K Buy
+34
New +$600 ﹤0.01% 1615

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Covestor's ALLO Position: Q1 2026 in Review

Covestor held its Allogene Therapeutics (ALLO) position steady in Q1 2026 at 36 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

Covestor first reported a position in ALLO in Q4 2021 and has held it in 18 quarters since. The position peaked at $1K in Q4 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Covestor held 36 shares of Allogene Therapeutics worth $0 as of Q1 2026.
  • Covestor left its Allogene Therapeutics share count unchanged in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2211 holding.
  • Covestor first reported a position in Allogene Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Covestor's Allogene Therapeutics position peaked at $1K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.